These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 7651362)

  • 1. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
    Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
    Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
    Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
    Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
    Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
    Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
    Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
    Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
    FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
    Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
    J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.
    Snider NT; Nast JA; Tesmer LA; Hollenberg PF
    Mol Pharmacol; 2009 Apr; 75(4):965-72. PubMed ID: 19171674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
    Deutsch DG; Lin S; Hill WA; Morse KL; Salehani D; Arreaza G; Omeir RL; Makriyannis A
    Biochem Biophys Res Commun; 1997 Feb; 231(1):217-21. PubMed ID: 9070252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.
    Facci L; Dal Toso R; Romanello S; Buriani A; Skaper SD; Leon A
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3376-80. PubMed ID: 7724569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
    Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
    Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
    Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
    Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
    Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
    Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups.
    Berglund BA; Boring DL; Wilken GH; Makriyannis A; Howlett AC; Lin S
    Prostaglandins Leukot Essent Fatty Acids; 1998 Aug; 59(2):111-8. PubMed ID: 9774174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
    Porter AC; Sauer JM; Knierman MD; Becker GW; Berna MJ; Bao J; Nomikos GG; Carter P; Bymaster FP; Leese AB; Felder CC
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1020-4. PubMed ID: 12023533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand.
    Khanolkar AD; Abadji V; Lin S; Hill WA; Taha G; Abouzid K; Meng Z; Fan P; Makriyannis A
    J Med Chem; 1996 Oct; 39(22):4515-9. PubMed ID: 8893848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
    Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
    Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
    van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
    J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
    Showalter VM; Compton DR; Martin BR; Abood ME
    J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.
    Skaper SD; Buriani A; Dal Toso R; Petrelli L; Romanello S; Facci L; Leon A
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):3984-9. PubMed ID: 8633002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat.
    Felder CC; Nielsen A; Briley EM; Palkovits M; Priller J; Axelrod J; Nguyen DN; Richardson JM; Riggin RM; Koppel GA; Paul SM; Becker GW
    FEBS Lett; 1996 Sep; 393(2-3):231-5. PubMed ID: 8814296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.